Almirall. 1Q19 results to be driven by acquisitions and product launches
Almirall. 1Q19 results to be driven by acquisitions and product launches
- Almirall will report its 1Q19 results on Monday 13th May.
- We expect +9% yoy sales growth in 1Q19e
- Allergan’s acquisition drives growth of sales
- Margins should increase
- We expect news on recent launches
- We reiterate our Buy recommendation
Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.
Bankinter S.A. is a Spanish brokerage firm established in 1989. The company's line of business includes the provision of market research and trading services for Equity and Fixed Income products.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.